Pantoprazol Normon (Pantoprazole)

Pantoprazol Normon is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders:

• Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of erosive esophagitis.
• Erosive oesophagitis: accelerates healing of mucosal breaks in the distal esophagus.
• Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence.
• Zollinger‑Ellison syndrome: controls hyper‑secretion of gastric acid.
• NSA‑ID‑associated gastric ulcer prophylaxis: lowers incidence of ulcer formation in at‑risk patients.

• Pantoprazole selectively and irreversibly binds to the H+/K+‑ATPase enzyme (the gastric proton pump) on the secretory surface of parietal cells. By inhibiting this final step of acid production, it markedly reduces both basal and stimulated gastric acidity, allowing mucosal healing and symptom control.

Pantoprazol Normon may cause adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhoea: watery stools, usually transient.
• Nausea: occasional feeling of queasiness.
• Abdominal pain: mild cramping or discomfort.
• Flatulence: increased intestinal gas.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Clostridioides difficile infection: severe colitis presenting with watery diarrhoea.
• Acute interstitial nephritis: kidney inflammation with reduced urine output.
• Severe hypersensitivity: rash, angio‑edema or anaphylaxis.
• Osteoporotic fractures: increased risk with long‑term use.
• Vitamin B12 deficiency: may develop after prolonged therapy.
• Hepatic impairment: elevated liver enzymes or jaundice.

Before initiating therapy, consider the following safety points:

• Assess renal function: dose adjustment may be required in severe impairment.
• Review hepatic status: use with caution in moderate to severe liver disease.
• Evaluate need for long‑term therapy: prolonged use is linked to bone density loss.
• Monitor for infection: proton pump inhibition can increase susceptibility to gastrointestinal infections.
• Avoid abrupt discontinuation: taper if therapy has been long‑term to reduce rebound acid hypersecretion.
• Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture.

Pantoprazole can affect the plasma concentrations of several co‑administered medicines.

Major Interactions (Avoid)

• Antifungal azoles (ketoconazole, itraconazole): reduced absorption due to increased gastric pH.
• HIV protease inhibitors (atazanavir, nelfinavir): decreased serum levels, risking therapeutic failure.
• Clopidogrel: diminished antiplatelet effect, potentially increasing cardiovascular risk.

Moderate Interactions (Monitor Closely)

• Warfarin: possible increase in INR, requiring more frequent monitoring.
• Digoxin: slight rise in serum concentration, may need dose adjustment.
• Methotrexate: reduced renal clearance at high doses, monitor renal function and drug levels.